MTOR and follicular lymphoma: Concordingly, when the Pan-PI3K inhibitors BEZ235 (Dactolisib; targets also mTOR and not yet approved for treatment) and BAY80-6946 (Copanlisib, Aliqopa®; approved for treatment of follicular lymphoma) were applied, similar death rates of senescent HCT166 cells compared to the treatment with PX-866 (Fig. 7, orange bar in all panels) were detected (Fig. 7B).